Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4757424
Max Phase: Preclinical
Molecular Formula: C29H27F4N3O4S
Molecular Weight: 589.61
Molecule Type: Unknown
Associated Items:
ID: ALA4757424
Max Phase: Preclinical
Molecular Formula: C29H27F4N3O4S
Molecular Weight: 589.61
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C(Nc1ccc2c(c1)C1(CCC(O)(C(F)(F)F)CC1)C(C1CC1)N2S(=O)(=O)c1ccc(F)cc1)c1cccnc1
Standard InChI: InChI=1S/C29H27F4N3O4S/c30-20-5-8-22(9-6-20)41(39,40)36-24-10-7-21(35-26(37)19-2-1-15-34-17-19)16-23(24)27(25(36)18-3-4-18)11-13-28(38,14-12-27)29(31,32)33/h1-2,5-10,15-18,25,38H,3-4,11-14H2,(H,35,37)
Standard InChI Key: ZBTKUCKWUZDEHZ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 589.61 | Molecular Weight (Monoisotopic): 589.1658 | AlogP: 5.57 | #Rotatable Bonds: 5 |
Polar Surface Area: 99.60 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.25 | CX Basic pKa: 3.51 | CX LogP: 4.69 | CX LogD: 4.69 |
Aromatic Rings: 3 | Heavy Atoms: 41 | QED Weighted: 0.38 | Np Likeness Score: -0.79 |
1. Panknin O,Wagenfeld A,Bone W,Bender E,Nowak-Reppel K,Fernández-Montalván AE,Nubbemeyer R,Bäurle S,Ring S,Schmees N,Prien O,Schäfer M,Friedrich C,Zollner TM,Steinmeyer A,Mueller T,Langer G. (2020) Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women., 63 (20): [PMID:32960053] [10.1021/acs.jmedchem.0c01076] |
Source(1):